Recurrent Rectal Cancer Clinical Trial
Official title:
Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination With Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer
This phase I/II trial is studying the side effects and best dose of sorafenib when given together with cetuximab and irinotecan and to see how well they work in treating patients with advanced or metastatic colorectal cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and cetuximab may also stop tumor growth by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to kill tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with cetuximab and irinotecan may kill more tumor cells
Status | Completed |
Enrollment | 48 |
Est. completion date | December 2011 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed colorectal cancer (advanced or metastatic disease not amenable to potential curative resection) - Archival tumor (blocks and/or slides) must be available for patients who decline tumor biopsies - Tumor must be amenable to sequential biopsies for patients willing to undergo tumor biopsy - Must have evidence of disease progression after first-line chemotherapy for advanced disease - Previously irradiated lesions are not considered measurable disease - Measurable disease, defined as >= 1 unidimensionally measurable target lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan - No known brain metastases - Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 60-100% - Life expectancy of more than 12 weeks - white blood cell count (WBC) >= 3,000/mm^3 - Bilirubin normal - Creatinine normal OR creatinine clearance >= 60 mL/min - No hypertension - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - Not pregnant or nursing - Able to swallow oral medication - Willing to undergo 2 sequential tumor and skin biopsies - No ongoing or active infection - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs - No psychiatric illness or social situation that would preclude study compliance - No other uncontrolled illness - No prior cetuximab - No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF) or epoetin alfa - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No other concurrent chemotherapy - More than 4 weeks since prior radiotherapy and recovered - No prior sorafenib - No other prior therapy targeted against MAPK - More than 14 days since prior and no concurrent administration of the following cytochrome P450 3A4 (CYP3A4) inducers: - Rifampin - Rifabutin - Hypericum perforatum (St. John's wort) - Phenytoin - Carbamazepine - Phenobarbital - More than 7 days since prior and no concurrent administration of the following CYP3A4 inhibitors: - Amiodarone - Clarithromycin - Diltiazem - Erythromycin - Grapefruit juice - Indinavir - Saquinavir - Lopinavir in combination with ritonavir - Fosamprenavir - Ritonavir - Atazanavir - Nelfinavir - Itraconazole - Ketoconazole - Nefazodone - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational agents - No other concurrent anticancer therapy - Negative pregnancy test - Fertile patients must use effective contraception - Absolute neutrophil count >=1,500/mm^3 - Platelet count = 100,000/mm^3 - No evidence of bleeding diathesis - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 times upper limit of normal |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado at Denver Health Sciences Center | Aurora | Colorado |
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity spectrum and dose-limiting toxicities of sorafenib in combination with cetuximab and irinotecan as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v 3.0 | Up to 30 days | Yes | |
Primary | Recommended dose for phase II evaluation of the combination of sorafenib, cetuximab and irinotecan | 56 days | No | |
Primary | Clinical activity of the combination of sorafenib, cetuximab and irinotecan in terms of radiological response | Up to 30 days | No | |
Primary | Pharmacokinetics of sorafenib, cetuximab, and irinotecan when given in combination or when given in combination with cetuximab alone and with cetuximab and irinotecan | Up to 30 days | No | |
Primary | Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues | Up to 30 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Active, not recruiting |
NCT00826540 -
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Recruiting |
NCT04642924 -
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01217450 -
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01285102 -
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
|
Phase 1 | |
Terminated |
NCT01238965 -
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00407654 -
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Completed |
NCT01740648 -
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
|
Phase 1 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 |